3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
2
NIH
1
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Breast
45
Tumor-Agnostic
2
Gynecologic
2
Genitourinary
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Endocrine
1
Conditions
Neoplasm Metastasis
1
Multiple Endocrine Neoplasia Type 1
1
Interventions
Everolimus
23
pasireotide
14
lutetium Lu 177 dotatate
10
Octreotide
10
lanreotide
9
surufatinib
8
Carboplatin
8
Paclitaxel
7
pembrolizumab
5
amino-acid, glucose, and electrolyte solution
5
Thyrotropin Alfa
5
Sunitinib
5
Nivolumab
5
Injections
5
3-Iodobenzylguanidine
5
relacorilant
4
fosbretabulin
4
Temozolomide
4
Fulvestrant
4
Etoposide
4
Data Collection
4
Cisplatin
4
vandetanib
3
selpercatinib
3
dabrafenib
3
anlotinib
3
Mifepristone
3
Lutetium-177
3
Lutetium
3
Irinotecan
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Tamoxifen
×
Endocrine
×
Clear all
NCT02753686
2023-02-15
Treat ER+ight
Novartis
Completed
440 enrolled